ABSTRACT
Many of the patients who attend the outpatient mental health clinics already have a long history of psychiatric problems. Their symptoms seem easy to classify, but the misdiagnosis of the patients' underlying problems can lead to a long series of costly referrals as inpatients or to an ineffective treatment outcome. In this article we focus on three patients whose history and background circumstances had been analysed in detail and who had also been subjected to a genetic analysis. The analyses pointed to an etiology-based diagnosis which had important implications for their future treatment and its outcome.
Subject(s)
Diagnostic Errors/psychology , Mental Disorders/diagnosis , Adult , Hospital Costs , Humans , Male , Mental Disorders/psychology , Middle Aged , Treatment OutcomeABSTRACT
Phelan-McDermid syndrome (PMS) or 22q13.3 deletion syndrome is characterized by a variable degree of intellectual disability, impaired speech and language as well as social communicative skills and mild dysmorphic features. The SHANK3 gene is thought to be a major contributor to the phenotype. Apart from the syndrome-associated autistic features, symptoms from the bipolar spectrum can be discerned, in particular behavior instability and fluctuating mood culminating in a (hypo)manic state. In case of coincident major somatic events, a deteriorating course may occur. This study comprises seven adult patients (four females and three males; aged 21-44 years) with genetically proven PMS. Data from medical records were collected and extensive assessment of neuropsychological variables was performed to identify cognitive characteristics and their relation with psychopathology and treatment. All patients showed profound communication deficits and their developmental functioning ranged from 1.0 to 6.3 years. In addition, they had slow speed of information processing, impairment of attentional and executive functions and cognitive alexithymia. As to psychopathology, features from the affective and anxiety domains were prominent findings in these seven patients suggesting the presence of a bipolar spectrum disorder that could be effectively moderated with mood-stabilizing agents. Results are discussed in terms of the putative involvement of structural brain abnormalities, in particular cerebellar vermis hypoplasia and corpus callosum thinning and their cognitive and emotional sequelae. It is concluded that the treatment of 22q13.3-associated psychopathology should include prescription of mood-stabilizing agents in combination with individually tailored contextual neuropsychological measures.
Subject(s)
Chromosome Disorders/psychology , Adult , Chromosome Deletion , Chromosome Disorders/genetics , Chromosome Disorders/physiopathology , Chromosome Disorders/therapy , Chromosomes, Human, Pair 22/genetics , Female , Humans , Male , Nerve Tissue Proteins/genetics , Phenotype , PsychopathologyABSTRACT
INTRODUCTION: This study includes 28 patients with genetically proven 22q11.2 deletion syndrome referred for treatment-resistant psychoses and aims at the identification of a suitable pharmacological treatment strategy. METHODS: Based on standardized diagnostic procedures, key psychiatric symptoms and cognitive status were assessed. Also, data about previous diagnostic vignettes as well as the history of psychotropic medication and medical conditions were collected. Finally, the effect of the subsequent treatment regimen was periodically re-assessed. RESULTS: Since psychotic symptoms had been shown to be non-responsive to conventional antipsychotics including risperidone, treatment with either clozapine or quetiapine was started. In 21 patients, a substantial reduction of psychotic symptoms was achieved with either one, and in 3-quarters of this group remission was attained over a longer follow-up period. In a significant number of patients, valproic acid was added either for mood stabilizing purposes or to avoid epileptic side effects of clozapine. DISCUSSION: Treatment of psychotic symptoms in patients with 22q11DS with the atypical antipsychotic quetiapine or clozapine in combination with the mood-stabilizing anticonvulsant valproic acid, appears likely to be more effective than with other psychotropic compounds.
Subject(s)
22q11 Deletion Syndrome/complications , Antipsychotic Agents/therapeutic use , Psychotic Disorders/drug therapy , Psychotic Disorders/etiology , Adult , Aged , Cognition Disorders/drug therapy , Cognition Disorders/etiology , Female , Humans , Longitudinal Studies , Male , Middle Aged , Neuropsychological Tests , Psychiatric Status Rating Scales , Recurrence , Treatment Outcome , Young AdultABSTRACT
BACKGROUND: Psychiatric disorders can be interpreted as a general dysregulation of the interplay between brain and behaviour. This is why, since the late 1990’s, the terms biological psychiatry and behavioural neurology have been gradually replaced by the term neuropsychiatry. Neuropsychiatry, when practiced in combination with clinical neuropsychology, have given rise to a paradigm that is not based solely on the usual classification models but is directed primarily towards diagnosis and treatment that are based on a functional-dimensional approach. AIM: To discuss the daily practice and organisation in a specialised department for neuro-psychiatry located in a psychiatric teaching hospital. METHOD: The interdisciplinary approach is explained and analysed on the basis of 10 case studies. RESULTS: Most of the patients referred to the specialised department already had a long history of visits to the health care facilities where they had been treated by a variety of specialists in single disciplines. Often, however, this trajectory did not involve periodical re-evaluation and updating of the original diagnosis. If this strategy had been adopted, then a clear diagnosis with simplified treatment programme might have been devised which could have resulted in a patient’s successful reintegration into society. CONCLUSION: It is essential that the interdisciplinary approach is adopted in specialised centres for neuropsychiatry because it can make an important contribution to individual patient care and to the spread of specialised knowledge that can benefit the entire field of psychiatry.
Subject(s)
Interdisciplinary Communication , Neuropsychology/organization & administration , Psychiatry/organization & administration , Quality of Health Care , Adolescent , Adult , Female , Humans , Male , Mental Disorders/diagnosis , Mental Disorders/therapy , Middle Aged , Neuropsychology/trends , Patient Care Team/organization & administration , Patient Care Team/trends , Psychiatry/trends , Young AdultABSTRACT
Aarskog-Scott syndrome [OMIM 100050] is a predominantly X-linked disorder that is phenotypically characterized by short stature, craniofacial dysmorphisms, brachydactyly and urogenital abnormalities. The level of intelligence shows a great variability and no specific behavioural phenotype has been described so far. In about 20 percent ofAarskog families, a mutation in the FGD1 gene located in Xp11.21 can be identified. In the present study, four affected males from the fourth generation of a large Dutch family (published in 1983 by Van de Vooren et al. (41)) are described. A novel FGD1 missense mutation (R402W) at position 1204 (1204C>T) was demonstrated. In the patients, the level of intelligence varied between normal and severely disabled. Their behavioural profile showed, among others, elements of attention deficit hyperactivity disorder, primarily reflected by impaired executive attentional processes that may be sensitive to systematic training.
Subject(s)
Abnormalities, Multiple/genetics , Attention Deficit Disorder with Hyperactivity/diagnosis , Cognition Disorders/genetics , Dwarfism/diagnosis , Dwarfism/genetics , Genetic Diseases, X-Linked/diagnosis , Genetic Diseases, X-Linked/genetics , Guanine Nucleotide Exchange Factors/genetics , Hand Deformities, Congenital/diagnosis , Hand Deformities, Congenital/genetics , Heart Defects, Congenital/diagnosis , Heart Defects, Congenital/genetics , Mutation, Missense/genetics , Abnormalities, Multiple/psychology , Adolescent , Adult , Attention Deficit Disorder with Hyperactivity/genetics , Attention Deficit Disorder with Hyperactivity/psychology , Chromosomes, Human, X/genetics , Cognition Disorders/diagnosis , Cognition Disorders/psychology , Dwarfism/psychology , Face/abnormalities , Genetic Diseases, X-Linked/psychology , Genitalia, Male/abnormalities , Hand Deformities, Congenital/psychology , Heart Defects, Congenital/psychology , Humans , Intellectual Disability/genetics , Intellectual Disability/psychology , Male , Neuropsychological Tests/statistics & numerical data , Polymorphism, Single-Stranded Conformational/genetics , Young AdultABSTRACT
Noonan syndrome (NS) is a genetic disorder characterised by short stature, facial dysmorphia, congenital heart defects and mildly lowered intellectual abilities. Research has mainly focused on genetic and somatic aspects, while intellectual and cognitive functioning has been documented scarcely. Also, to date studies have been primarily performed in children. This is the first study in which functioning within the major cognitive domains is systematically evaluated in a group of adults with NS and compared with a control group. Extensive neuropsychological assessment, including the domains intelligence, speed of information processing, memory (working memory, immediate recall and delayed recall), executive function and visuoconstruction, was performed in a sample of 42 patients with NS and 42 healthy controls, matched on age, sex and education level. In addition, subjective cognitive complaints were assessed with self-report questionnaires. On the domain speed of information processing patients performed worse than controls (P < 0.05). Furthermore, except for slightly better results on delayed recall in the patients with NS (P < 0.05), none of the other cognitive domains showed between-group differences. On the questionnaires, patients reported substantially more complaints about their own cognitive abilities than controls (P < 0.05). A lowered speed of information processing and relatively intact functioning in other cognitive domains characterises the cognitive profile of adult patients, in contrast to previous findings in children with NS, who seem to have more generalised cognitive deficits.
Subject(s)
Cognition , Intelligence/genetics , Noonan Syndrome/psychology , Adolescent , Adult , Case-Control Studies , Executive Function , Female , Humans , Male , Memory , Middle AgedABSTRACT
BACKGROUND: Noonan syndrome (NS) is a common genetic disorder, characterized by short stature, facial dysmorphia, congenital heart defects and a mildly lowered IQ. Impairments in psychosocial functioning have often been suggested, without, however, systematic investigation in a clinical group. In this study, different aspects of affective processing, social cognition and behaviour, in addition to personal well-being, were assessed in a large group of patients with NS. METHOD: Forty adult patients with NS were compared with 40 healthy controls, matched with respect to age, sex, intelligence and education level. Facial emotion recognition was measured with the Emotion Recognition Task (ERT), alexithymia with both the 20-item Toronto Alexithymia Scale (TAS-20) and the Bermond-Vorst Alexithymia Questionnaire (BVAQ), and mentalizing with the Theory of Mind (ToM) test. The Symptom Checklist-90 Revised (SCL-90-R) and the Scale for Interpersonal Behaviour (SIB) were used to record aspects of psychological well-being and social interaction. RESULTS: Patients showed higher levels of cognitive alexithymia than controls. They also experienced more social distress, but the frequency of engaging in social situations did not differ. Facial emotion recognition was only slightly impaired. CONCLUSIONS: Higher levels of alexithymia and social discomfort are part of the behavioural phenotype of NS. However, patients with NS have relatively intact perception of emotions in others and unimpaired mentalizing. These results provide insight into the underlying mechanisms of social daily life functioning in this patient group.
Subject(s)
Affective Symptoms/physiopathology , Interpersonal Relations , Noonan Syndrome/physiopathology , Social Perception , Adolescent , Adult , Facial Expression , Female , Humans , Male , Middle Aged , Noonan Syndrome/genetics , Theory of Mind/physiology , Young AdultABSTRACT
Clozapine has a narrow therapeutic range. The threshold value for plasma concentrations is 350 µg/l. If plasma concentrations exceed that value, serious side-effects can occur. An increase in plasma concentrations can occur as a result of inflammatory processes which may or may not be caused by an infection. Two cases are discussed in which the plasma concentration of clozapine increased as a result of an inflammatory reaction and signs of intoxication were observed. These developments seemed to be due to cholecystitis and bacterial pneumonia respectively. The clinical presentation and pathophysiology are discussed in relation to inflammatory processes.
Subject(s)
Antipsychotic Agents/blood , Cholecystitis/blood , Clozapine/blood , Pneumonia, Bacterial/blood , Adult , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Clozapine/adverse effects , Clozapine/therapeutic use , Drug Monitoring , Humans , Male , Middle Aged , Schizophrenia/blood , Schizophrenia/drug therapyABSTRACT
OBJECTIVE: Sanfilippo B is a rare autosomal recessive mucopolysaccharidosis (MPS IIIB) caused by a deficiency of N-acetyl-alpha-D-glucosaminidase (NAGLU). METHOD: A mild mentally retarded elderly female patient is described with a slowly progressive dementia who had given birth to a daughter who developed normally. RESULTS: Metabolic screening revealed an enhanced concentration of heparan sulfate in urine. Enzymatic assay demonstrated deficiency of N-acetyl-alpha-D-glucosaminidase. Mutations in the NAGLU gene were found. One mentally retarded and hospitalized elder brother was also found to have MPS IIIB, whereas a second brother, who had died earlier, is suspected to have had the same metabolic disorder. Prior to the development of dementia, both the patient and her brother showed autistic like features, signs of ideomotor apraxia and weakness in verbal comprehension. CONCLUSION: Screening for metabolic disorders, in particular MPSes, should always be considered in patients with a history of mental deficit and dementia or progressive functional decline.
Subject(s)
Alzheimer Disease/diagnosis , Mucopolysaccharidosis III/diagnosis , Acetylglucosaminidase/deficiency , Alzheimer Disease/genetics , Alzheimer Disease/psychology , Atrophy , Brain/pathology , Chromosome Aberrations , Diagnosis, Differential , Female , Genes, Recessive/genetics , Heparitin Sulfate/urine , Humans , Intellectual Disability/diagnosis , Intellectual Disability/genetics , Intellectual Disability/psychology , Magnetic Resonance Imaging , Middle Aged , Mucopolysaccharidosis III/genetics , Mucopolysaccharidosis III/psychologyABSTRACT
Subjects with Down syndrome (DS) have abnormalities in virtually all aspects of the immune system and almost all will be affected with Alzheimer's disease (AD). It is thought that nitric oxide (NO) is involved in the pathophysiology of AD. In the present study, including a total of 401 elderly DS subjects, the spectrum of plasma amino acids and neopterin was investigated and related to development of AD. Concentrations of nearly all amino acids in DS subjects differed significantly from those of healthy controls. Neopterin was increased in DS subjects, especially in dementia. The production of NO as reflected by an increased citrulline/arginine ratio (Cit/Arg ratio) was enhanced during development of clinical dementia. Neopterin concentrations correlated to the Cit/Arg ratio only in the group of prevalent demented subjects (rho = 0.48, P = 0.006). The results of this study are suggestive for an increase in oxidative processes in DS subjects with AD.
Subject(s)
Amino Acids/blood , Dementia/blood , Down Syndrome/blood , Neopterin/blood , Nitric Oxide/metabolism , Alzheimer Disease/blood , Alzheimer Disease/complications , Amino Acids/metabolism , Amino Acids, Aromatic/blood , Amino Acids, Branched-Chain/blood , Arginine/blood , Citrulline/blood , Cohort Studies , Dementia/complications , Dementia/epidemiology , Depression/blood , Depression/complications , Depression/drug therapy , Down Syndrome/complications , Down Syndrome/physiopathology , Epilepsy/blood , Epilepsy/complications , Epilepsy/drug therapy , Female , Humans , Intellectual Disability/physiopathology , Male , Middle Aged , Oxidative Stress , Severity of Illness IndexABSTRACT
BACKGROUND: The diagnosis of Rubinstein-Taybi syndrome (RTS) is primarily clinical and based on the characteristic phenotype that is often combined with a variety of somatic anomalies and psychiatric disorders. SAMPLING AND METHODS: In this paper, a review is presented of the psychiatric and behavioural aspects of RTS. This is illustrated with a case report. RESULTS: Behavioural aspects of about 150 patients are described, and include a variable degree of mental retardation, impulsivity, distractibility, instability of mood and stereotypies. In general, patients with RTS are described as sociable and friendly. Information about brain pathology is virtually absent. In about half of the cases, the syndrome is caused by a mutation or deletion of the CREB-binding protein (CBP) gene (16p13.3). The case report deals with an adult male who was referred for impulsivity and temper outbursts. A provisional diagnosis of atypical depression was made, and treatment with citalopram resulted in a remarkable amelioration of his mood and behaviour that persisted for more than 2 years (last observation). CONCLUSION: Patients with undetected genetic syndromes do occur in clinical psychiatry, and the clinician has to consider such disorders in cases with disturbed development, dysmorphias and somatic comorbidity.
Subject(s)
Depressive Disorder/diagnosis , Depressive Disorder/psychology , Disruptive, Impulse Control, and Conduct Disorders/diagnosis , Disruptive, Impulse Control, and Conduct Disorders/psychology , Intellectual Disability/diagnosis , Intellectual Disability/psychology , Rubinstein-Taybi Syndrome/diagnosis , Rubinstein-Taybi Syndrome/psychology , Adult , CREB-Binding Protein/genetics , Chromosome Deletion , Chromosomes, Human, Pair 22/genetics , DNA Mutational Analysis , Depressive Disorder/genetics , Diagnosis, Differential , Disruptive, Impulse Control, and Conduct Disorders/genetics , E1A-Associated p300 Protein/genetics , Humans , Intellectual Disability/genetics , Male , Neuropsychological Tests/statistics & numerical data , Phenotype , Psychometrics , Rubinstein-Taybi Syndrome/geneticsABSTRACT
BACKGROUND: Psychiatric treatment of mentally handicapped patients is still in its infancy because these patients are diagnosed by means of inadequate DSM vignettes that were not developed for such a homogeneous group and that do not have the status of diagnoses based on aetiology and pathophysiology. AIM: To raise awareness that the psychiatrist dealing with this group of patients needs to have a thorough knowledge of the syndromes involved which can be accompanied by psychiatric and somatic comorbidity and also needs to have expertise in linked disciplines such as genetics, epileptology and pharmacology. METHOD: On the basis of the international scientific literature an attempt was made to identify the rationale that underlies the current practice of treating challenging behaviour with a fairly random selection of psychotropics. RESULT: A diagnostic algorithm was formulated which can help the psychiatrist to provide evidence-based specialised advice on treatment and which can also prevent the occurrence of harm or damage. CONCLUSION: The top-down orientation of current diagnostic procedures, which tries to link symptoms to an underlying pathology, should be counterbalanced by a bottom-up approach in which the aetiology is the starting point. If this principle is observed, a well-founded proposal about treatment can sometimes be put forward. In all other cases treatment at present is little more than symptomatic pharmacotherapy involving a few well-documented psychotropics.
Subject(s)
Intellectual Disability/diagnosis , Intellectual Disability/therapy , Persons with Mental Disabilities/psychology , Psychotropic Drugs/therapeutic use , Algorithms , Diagnosis, Differential , Evidence-Based Medicine , Humans , Intellectual Disability/psychology , PsychotherapyABSTRACT
In a 37-year-old female, a combined treatment consisting of chemotherapy and radiation was considered for cervical cancer. However, she was using clozapine for the treatment of schizophrenia. As both clozapine and chemotherapy can induce decrease of white blood cell counts, we had to decide if clozapine and chemotherapy could be safely co-prescribed. Hypotheses concerning the mechanisms underlying clozapine-induced decrease of white blood cell counts and case reports on combining chemotherapy and clozapine are discussed. After cessation of clozapine the psychosis recurred despite treatment with risperidone. The decision was made to administer radiotherapy only and to reinstate the treatment with clozapine. The radiotherapy treatment went according to plan and the psychosis receded.
Subject(s)
Agranulocytosis/chemically induced , Antineoplastic Agents/adverse effects , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Antipsychotic Agents/adverse effects , Clozapine/adverse effects , Adult , Antineoplastic Agents/therapeutic use , Antipsychotic Agents/therapeutic use , Clozapine/therapeutic use , Drug Interactions , Female , Humans , Schizophrenia/drug therapy , Uterine Cervical Neoplasms/drug therapy , Uterine Cervical Neoplasms/radiotherapyABSTRACT
BACKGROUND: Meditation is a self-regulatory psychological strategy that is frequently applied in Western as well as non-Western countries for different purposes; little is known about adverse events. SAMPLING AND METHODS: A male patient is described who developed an acute and transient psychosis with polymorphic symptomatology after meditating. A literature search for psychotic states related to meditation was carried out on PubMed, Embase and PsycInfo. RESULTS: In the case presented a diagnosis of acute polymorphic psychotic disorder was made. Other case reports dealt with either a relapse of a pre-existent psychotic disorder or with a brief psychotic reaction in patients without a psychiatric history. CONCLUSION: Meditation can act as a stressor in vulnerable patients who may develop a transient psychosis with polymorphic symptomatology. The syndrome is not culture bound but sometimes classified in culture-bound taxonomies like Qi-gong Psychotic Reaction.
Subject(s)
Meditation/psychology , Psychotic Disorders/etiology , Psychotic Disorders/psychology , Adult , Cultural Characteristics , Humans , Male , Psychotic Disorders/ethnology , Stress, Psychological , SyndromeABSTRACT
Hypothalamic hamartomas (HH) are developmental malformations that are associated with gelastic seizures, other types of seizures, cognitive decline, and symptoms related to hypothalamic dysfunction. Although aggressive behavior is frequently described, data on the neuropsychiatric profile are limited. In this article, five patients with HH are described who displayed a wide variety of psychiatric symptoms that, dependent on the time frame, met the criteria for several categorical diagnoses. Major neuropsychiatric symptoms comprised aggression that is only partial context dependent, compulsive behavior, psychotic symptoms not responding to treatment, and organic mood instability. HH should therefore be considered a neuropsychiatric syndrome with a highly variable expression that can be best captured by a thorough description of behaviors, symptoms, sequelae of epilepsy, and hypothalamic dysfunction.
Subject(s)
Behavioral Symptoms/etiology , Hamartoma/complications , Hamartoma/psychology , Hypothalamic Neoplasms/complications , Hypothalamic Neoplasms/psychology , Adult , Aggression , Compulsive Behavior , Female , Humans , Male , Middle Aged , Mood DisordersABSTRACT
In this paper a review is presented of the rare combination of Klinefelter's syndrome and Prader-Willi syndrome (PWS) and a second case of this combination with a uniparental disomy (UPD) etiology of PWS is described. Patients outlined in all other 8 reports and the present case have a PWS phenotype. Virtually no information is available on the behavioral and psychopathological phenotype in this combination. The latter may be explained by the observation that psychiatric syndromes are especially prevalent in PWS patients with a UPD. It is concluded that instability in mood and behavior in this and other syndromes should be preferentially treated with mood stabilizing agents.
Subject(s)
Klinefelter Syndrome/complications , Prader-Willi Syndrome/complications , Adult , Chromosomes, Human, Pair 15/genetics , Humans , Karyotyping , Klinefelter Syndrome/diagnosis , Klinefelter Syndrome/genetics , Male , Microsatellite Repeats/genetics , Phenotype , Prader-Willi Syndrome/diagnosis , Prader-Willi Syndrome/genetics , Uniparental DisomyABSTRACT
A 24-year-old man who was mentally retarded and had an autistic disorder, developed mutism and motor symptoms. He was diagnosed with catatonia and was treated successfully with lorazepam. Additionally, we review the literature about the diagnosis and treatment of catatonia in patients with autism; in such cases accurate diagnosis is vital but is complicated by overlapping symptoms.
Subject(s)
Autistic Disorder/complications , Catatonia/drug therapy , Hypnotics and Sedatives/therapeutic use , Lorazepam/therapeutic use , Adult , Catatonia/diagnosis , Catatonia/etiology , Humans , Male , Treatment OutcomeSubject(s)
Psychotic Disorders/etiology , Telangiectasia, Hereditary Hemorrhagic/psychology , Adult , Antigens, CD/genetics , Brain/diagnostic imaging , Brain/pathology , Brain/physiopathology , Endoglin , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Psychotic Disorders/diagnosis , Psychotic Disorders/psychology , Receptors, Cell Surface/genetics , Severity of Illness Index , Telangiectasia, Hereditary Hemorrhagic/diagnosis , Telangiectasia, Hereditary Hemorrhagic/genetics , Tomography, X-Ray ComputedABSTRACT
In persons with Down's syndrome (DS) immunological abnormalities as well as hypothyroidism and Alzheimer type dementia are frequently observed. In addition, the activity of the enzyme cystathionine beta-synthase (CBS) is over-expressed which results in an altered homocysteine metabolism. In the present study, 48 older healthy DS persons without signs of dementia, psychiatric or somatic comorbidity and free of medication were analyzed for plasma levels of amino acids, neopterin and monoaminergic metabolites. Data were compared with those obtained from age and sex matched healthy controls. It was found that the spectrum of amino acids showed widespread differences in that levels of nearly all essential amino acids were lower in DS patients as compared to healthy controls. In addition, a significantly lower methionine and higher taurine concentration were observed which is in accordance with a disturbed homocysteine metabolism. With respect to the monoamine metabolites, the concentration of 5-hydroxyindoleacetic acid was not altered whereas that of homovanillic acid was significantly increased. Finally, the concentration of the immune activation marker neopterin was increased in persons with DS. It is concluded that healthy DS persons of older age show extensive biochemical abnormalities suggesting a compromised homocysteine metabolism, an activated cell-mediated immune response and an enhanced turnover of dopamine.
Subject(s)
Amino Acid Metabolism, Inborn Errors/blood , Amino Acids/blood , Dopamine/metabolism , Down Syndrome/blood , Immune System Diseases/blood , Neopterin/blood , Aged , Biomarkers/analysis , Biomarkers/blood , Comorbidity , Female , Homocysteine/metabolism , Homovanillic Acid/blood , Humans , Immune System Diseases/immunology , Immunity, Cellular/immunology , Male , Methionine/blood , Middle Aged , Taurine/blood , Up-Regulation/physiologyABSTRACT
Over the last few decades much research has been done into the raised level of psychiatric comorbidity in epilepsy. On the basis of a case study of a patient suffering from post-ictal psychoses we explain the psychiatric differential diagnosis within the framework of epilepsy and we investigate the frequent psychiatric side-effects of anticonvulsants. It is concluded that the links between epilepsy and psychiatric symptoms are complex and that the neuropsychiatry of epilepsy is concerned with syndromes that are unique and do notfit into modern psychiatric classification systems.